News | Radiation Therapy | October 18, 2016

Yale research suggests patients treated at higher-volume facilities were more likely to have improved survival, shorter radiotherapy duration

intensity modulated radiation therapy outcomes, IMRT, head and neck cancers, facility volume, ASTRO 2016

October 18, 2016 — The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival. The findings were presented Sept. 26 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.

This study used the National Cancer Data Base to analyze 9,817 patients and found that patients treated at higher-volume facilities were more likely to have shorter radiation therapy duration than those at lower volume facilities.

The research team’s findings also revealed there was a 5.7 percent decreased hazard of death per additional 20 patients treated per year per facility. When annual facility case volume was defined based on a threshold of 95 cases/year (90th percentile), there was a 17.5 percent decreased hazard of death for higher-volume versus lower-volume facilities.

“Our findings suggest a strong relationship between higher-volume radiation therapy facilities and improved overall survival for patients treated with IMRT for locally advanced head and neck cancers,” said Henry S. Park, MD, MPH, first author on the study and a chief resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Further investigation should focus on the role of other factors potentially underlying this association, including radiation contouring, education, multidisciplinary communication, and toxicity management.”

For more information: www.astro.org


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Stereotactic Body Radiation Therapy (SBRT) | American Society for Radiation Oncology

Sept. 29, 2025 — A new clinical trial report finds that stereotactic radiation therapy offers long-term survival ...

Time October 15, 2025
arrow
News | Proton Therapy

Sept. 28, 2025 — Leo Cancer Care has launched Grace, the company's upright photon therapy system. Grace is named after ...

Time October 03, 2025
arrow
News | Radiation Therapy | American Society for Radiation Oncology (ASTRO)

Sept. 29, 2025 — Radiation therapy may offer a comparable and potentially safer alternative to repeat catheter ablation ...

Time September 30, 2025
arrow
News | Radiation Therapy

Sept. 26, 2025 – Accuray Inc. has introduced the Accuray Stellar* solution. Initially for the U.S. market, the new ...

Time September 29, 2025
arrow
News | Computed Tomography (CT)

Sept. 26, 2025 — At the American Society for Radiation Oncology (ASTRO) 2025 annual meeting in San Francisco, Calif ...

Time September 29, 2025
arrow
News | Lung Imaging

Sept. 26, 2025 ― Researchers from the University of Texas MD Anderson Cancer Center will present new data at the ...

Time September 29, 2025
arrow
News | ASTRO

Sept. 26, 2025 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time September 29, 2025
arrow
News | Radiation Therapy

Sept. 25, 2025 — GE HealthCare has announced updates to Intelligent Radiation Therapy (iRT), a new version of the ...

Time September 25, 2025
arrow
Subscribe Now